<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743221</url>
  </required_header>
  <id_info>
    <org_study_id>CL2-95005-002</org_study_id>
    <nct_id>NCT02743221</nct_id>
  </id_info>
  <brief_title>A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy</brief_title>
  <acronym>TASCO1</acronym>
  <official_title>An Open-label, Randomised, Non-comparative Phase 2 Study Evaluating S 95005 (TAS-102) Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Metastatic COlorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1 Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the progression-free survival (PFS) in patients
      receiving S 95005 + bevacizumab (experimental arm) or capecitabine + bevacizumab (control
      arm) as first-line treatment for unresectable metastatic colorectal cancer in patients
      non-eligible for intensive therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Actual">January 15, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 12 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>Up to 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 2 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed by incidence of Adverse Events</measure>
    <time_frame>Up to 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed by laboratory tests</measure>
    <time_frame>Up to 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed by physical examination</measure>
    <time_frame>Up to 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed by performance status (ECOG)</measure>
    <time_frame>Up to 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed by vital signs</measure>
    <time_frame>Up to 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed by 12-leads ECG parameters</measure>
    <time_frame>Up to 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessed by a quality of life questionnaire.</measure>
    <time_frame>Up to 12 months.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Circulating protein biomarkers analysis</measure>
    <time_frame>through study completion, an average of 12 months</time_frame>
    <description>Samples collected at C1D1 (day 1 of cycle 1) and at withdrawal will be subjected to Dproteomic analysis for identification of potential predictive and resistance biomarkers for S 95005 and/or bevacizumab response or biological activity in comparison to capecitabine + bevacizumab arm. Biomarkers in relation to the metabolic pathway of S 95005 and capecitabine will be assessed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Circulating tumour DNA analysis</measure>
    <time_frame>day 1 of cycle 1 (each cycle is 28 days)</time_frame>
    <description>Samples collected at C1D1 will be subjected to genomic analysis to study mutations currently observed in colorectal cancer</description>
  </other_outcome>
  <other_outcome>
    <measure>Proteomic analysis on archived biopsy</measure>
    <time_frame>day 1 of cycle 1 (each cycle is 28 days)</time_frame>
    <description>Archived biopsy collected at metastatic stage diagnosis, will be recovered at C1D1 and subjected to proteomic analysis in relation to the metabolic pathway of S 95005 and capecitabine for identification of biomarkers that may predict response to S 95005 and capecitabine in combination with bevacizumab</description>
  </other_outcome>
  <other_outcome>
    <measure>Genomic analysis on archived biopsy</measure>
    <time_frame>day 1 of cycle 1 (each cycle is 28 days)</time_frame>
    <description>Archived biopsy collected at metastatic stage diagnosis, will be recovered at C1D1 and subjected to microsatellite instability analysis for identification of biomarkers that may predict response to S 95005 and capecitabine in combination with bevacizumab</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>S 95005 + bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine + bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifluridine/tipiracil hydrochloride (S 95005)</intervention_name>
    <description>film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, taken orally twice a day at the dose of 35 mg/m2/dose, until a discontinuation criterion is met</description>
    <arm_group_label>S 95005 + bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine film-coated tablets containing 150 mg or 500 mg of capecitabine taken orally twice a day at the dose of 1250 mg/m2/dose, until a discontinuation criterion is met</description>
    <arm_group_label>Capecitabine + bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>concentrate for solution for infusion containing 25mg/ml of bevacizumab administered intravenously at the dose of 5 mg/kg, until a discontinuation criterion is met</description>
    <arm_group_label>S 95005 + bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>concentrate for solution for infusion containing 25mg/ml of bevacizumab administered intravenously at the dose of 7.5 mg/kg, until a discontinuation criterion is met</description>
    <arm_group_label>Capecitabine + bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained.

          -  Male or Female participant aged â‰¥18 years old.

          -  Has ECOG performance status of 0, 1 or 2 at the time of the randomisation.

          -  Has definitive histologically or cytologically confirmed adenocarcinoma of the colon
             or rectum.

          -  RAS status must have been determined (mutant or wild).

          -  Has at least one measurable metastatic lesion.

          -  No previous systemic anticancer therapy for unresectable metastatic colorectal cancer.

          -  Previous adjuvant (or neoadjuvant for patients with rectal cancer) chemotherapy is
             allowed only if if it has been completed more than 6 months before start of study
             treatment.

          -  Patient is not a candidate for combination chemotherapy with irinotecan or
             oxaliplatin, or for curative resection of metastatic lesions.

          -  Is able to take medication orally (i.e., no feeding tube).

          -  Has adequate organ function.

          -  Coagulation parameters in normal limit (or in therapeutic limit for patients treated
             with anticoagulant drugs).

          -  Women of childbearing potential must have been tested negative in a serum pregnancy
             test. Female participants of childbearing potential and male participants with
             partners of childbearing potential must agree to use a highly effective method of
             birth control. Women and female partners using hormonal contraceptive must also use a
             barrier method.

          -  Is willing and able to comply with scheduled visits and study procedures.

        Exclusion Criteria:

          -  Foreseeable poor compliance to the study procedures.

          -  Is a pregnant or lactating female.

          -  Is inappropriate for entry into this study in the judgment of the Investigator.

          -  Has certain serious illness or serious medical condition(s) described in the protocol.

          -  Has had certain other recent treatment e.g. major surgery, field radiation, received
             investigational agent, within the specified time frames prior to randomisation.

          -  Has previously received S 95005 or history of allergic reactions attributed to
             compounds of similar composition to S 95005 or any of its excipients.

          -  Has rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or
             glucose-galactose malabsorption.

          -  Has contra-indication to bevacizumab or capecitabine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Van Custem, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leuven Cancer Institute, University Hospitals Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Austin Hospital, Olivia Newton-John Cancer &amp; Wellness Centre</name>
      <address>
        <city>Heidelberg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Health, Sunshine Hospital</name>
      <address>
        <city>St Albans</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi, Oncologie MÃ©dicale</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Campus Gasthuisberg, Gastroenterology/Digestive Oncology</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Les Cliniques Saint-Joseph, Oncology Dpt</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital do CÃ¢ncer de Barretos - FundaÃ§Ã£o Pio XII</name>
      <address>
        <city>Barretos</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Hospital de Caridade de IjuÃ­</name>
      <address>
        <city>Ijui</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Base, Centro Intergrado de Pesquisa</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Copenhagen, Oncology Department</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitets hospital, Department of Oncology</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz, Service d'oncologie mÃ©dicale</name>
      <address>
        <city>BesanÃ§on</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Saint Antoine, oncology department</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre RenÃ© Gauducheau, Oncologie MÃ©dicale</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis KurfÃ¼rstendamm</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis fÃ¼r HÃ¤matologie und Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>StÃ¤dtisches Krankenhaus MÃ¼nchen Neuperlach, Klinik fÃ¼r Onkologie und HÃ¤matologie</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Poliambulanza Istituto Ospedaliero, Clinical Oncology</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. SanMartino-IST, UnitÃ  Operativa Oncologia Medica 1</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale Niguarda Ca' Granda-Milano, Department of Onco-Haematology- Onoclogia Falck</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seconda UniversitÃ  degli Studi di Napoli, U.O.C. di Oncologia Medica ed Ematologia</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>.O.U. Pisana-Ospedale Santa Chiara, U.O. di Oncologia Medica 2</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. dr. C.J.A. (Kees) Punt, Dept of Medical Oncology, room F4-224, Academic Medical Center, University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis, Interne Geneeskunde/Oncologie, Langendijk 75</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis, Interne Geneeskunde/Oncologie</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuizen, Interne Geneeskunde/Oncologie, Van Swietenplein 1</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tergooi Hilversum, Medische Oncologie, Van Riebeeckweg 212</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orbis Medisch Centrum, nu : Zuyderland Medisch Centrum, Dr. H. van der Hoffplein 1</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antoniusziekenhuis, Interne Geneeskunde/Oncologie, Soestwetering 1</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VieCurie Medisch Centrum, Interne Geneeskunde, Tegelseweg 210</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken, Medische oncologie, Dokter Van Heeweg 2</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CENTRUM ONKOLOGII Oddzial w Krakowie, Klinika Nowotworow Ukladowych i Uogolnionych</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SZPITAL UNIWERSYTECKI W KRAKOWIE, Oddzial Kliniczny Onkologii</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital of Ministry of Interior</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ MAGODENT, Oddzial Onkologii Klinicznej / Chemioterapii</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Oncology Hospital # 62, Chemotherapy</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Cancer Research Center n.a. NN Blokhin</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Centre for Specialized Medical Care (oncological)</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Valle de HebrÃ³n, Servicio de OncologÃ­a</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan De OncologÃ­a, Hospitalet de Llobregat</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia, Deparatmento OncologÃ­a MÃ©dica</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital la Paz, OncologÃ­a MÃ©dica</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital RamÃ³n y Cajal, OncologÃ­a MÃ©dica</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario, OncologÃ­a MÃ©dica</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra, OncologÃ­a MÃ©dica</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Beatson West of Scotland Cancer Centre GI cancers</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary, The HOPE Clinical Trials Unit</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Foundation Trust, GI &amp; Endocrine</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital, Rickmansworth</name>
      <address>
        <city>Middlesex</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <keyword>colorectal</keyword>
  <keyword>cancer</keyword>
  <keyword>untreated</keyword>
  <keyword>first-line</keyword>
  <keyword>S95005</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trifluridine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).
They can ask all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

